SARS-CoV-2 in Pregnancy, Birth and Puerperium. Guideline of the DGGG and DGPM (S2k-Level, AWMF Registry Number 015/092, March 2022)

. 2023 Mar 9;83(5):517–546. doi: 10.1055/a-2003-5983

Consensus-based recommendation 8.E42
A pregnant woman with SARS-CoV-2 infection must be given antenatal steroids for fetal indications if she shows signs of clinical worsening (e.g., intubation/ECMO is planned) between weeks 23 + 5 and 34 + 0 of gestation (2 × 12 mg betamethasone/celestan administered intramuscularly (IM) with an interval of 24 h between doses); alternatively, the patient may be treated with dexamethasone (IM) 4 × 6 mg every 12 h. It is currently not possible to answer the question whether betamethasone is equivalent to dexamethasone with regards to COVID-19.

Consensus-based recommendation 8.E42

Expert consensus

Level of consensus +++

A pregnant woman with SARS-CoV-2 infection must be given antenatal steroids for fetal indications if she shows signs of clinical worsening (e.g., intubation/ECMO is planned) between weeks 23 + 5 and 34 + 0 of gestation (2 × 12 mg betamethasone/celestan administered intramuscularly (IM) with an interval of 24 h between doses); alternatively, the patient may be treated with dexamethasone (IM) 4 × 6 mg every 12 h.
It is currently not possible to answer the question whether betamethasone is equivalent to dexamethasone with regards to COVID-19.